Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report
Key Clinical Message In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. Abstract An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.7365 |
| _version_ | 1797820482246934528 |
|---|---|
| author | Wei Sun Xinlian Wang Qifeng Shi Xiao Li Chaobo Chen |
| author_facet | Wei Sun Xinlian Wang Qifeng Shi Xiao Li Chaobo Chen |
| author_sort | Wei Sun |
| collection | DOAJ |
| description | Key Clinical Message In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. Abstract An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines. |
| first_indexed | 2024-03-13T09:38:57Z |
| format | Article |
| id | doaj.art-f59971f1a7914a66992b99789018d9a3 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-03-13T09:38:57Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-f59971f1a7914a66992b99789018d9a32023-05-25T05:58:40ZengWileyClinical Case Reports2050-09042023-05-01115n/an/a10.1002/ccr3.7365Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case reportWei Sun0Xinlian Wang1Qifeng Shi2Xiao Li3Chaobo Chen4Department of Respiratory and Critical Care Xishan People's Hospital of Wuxi City Wuxi ChinaDepartment of Cardiothoracic Surgery Xishan People's Hospital of Wuxi City Wuxi ChinaDepartment of Pathology Xishan People's Hospital of Wuxi City Wuxi ChinaDepartment of Pathology the First Affiliated Hospital of Nanjing Medical University Nanjing ChinaDepartment of General Surgery Xishan People's Hospital of Wuxi City Wuxi ChinaKey Clinical Message In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. Abstract An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines.https://doi.org/10.1002/ccr3.7365antiangiogenetic therapychemotherapygenetic testingnon‐small cell lung cancer (NSCLC)pulmonary sarcomatoid carcinomaROS1 |
| spellingShingle | Wei Sun Xinlian Wang Qifeng Shi Xiao Li Chaobo Chen Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report Clinical Case Reports antiangiogenetic therapy chemotherapy genetic testing non‐small cell lung cancer (NSCLC) pulmonary sarcomatoid carcinoma ROS1 |
| title | Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report |
| title_full | Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report |
| title_fullStr | Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report |
| title_full_unstemmed | Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report |
| title_short | Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report |
| title_sort | comprehensive treatment for ros1 overexpressed pulmonary sarcomatoid carcinoma a case report |
| topic | antiangiogenetic therapy chemotherapy genetic testing non‐small cell lung cancer (NSCLC) pulmonary sarcomatoid carcinoma ROS1 |
| url | https://doi.org/10.1002/ccr3.7365 |
| work_keys_str_mv | AT weisun comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport AT xinlianwang comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport AT qifengshi comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport AT xiaoli comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport AT chaobochen comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport |